Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Colloid Interface Sci ; 582(Pt A): 364-375, 2021 Jan 15.
Article in English | MEDLINE | ID: mdl-32861041

ABSTRACT

Oral delivery of protein or peptide drugs confronts several barriers, the intestinal epithelium and the mucus barrier on the gastrointestinal tract is deemed to be the toughest obstacles. However, overcoming these two obstacles requires contradictory surface properties of a nanocarrier. In the present work, mesoporous silica nanoparticles (MSNs) were modified with deoxycholic acid (DC) and coated with sulfobetaine 12 (SB12) for the first time to achieve both improved mucus permeation and transepithelial absorption. MSNs modified with stearic acid and coated with dilauroylphosphatidylcholine (DLPC) or Pluronic P123 were also prepared as controls. The SB12 coated DC modified MSN had high drug loading of 22.2%. The zwitterion coating endows the MSN improved mucus penetrating ability. In addition, the carrier also showed remarkable affinity with epithelial cells. The cellular uptake was significantly improved (10-fold for Caco-2 cells and 8-fold for E12 cells). The results also indicated that the DC modified carrier was able to avoid entry into lysosomes. It can increase the absorption of loaded insulin in all intestine segments and showed outstanding hypoglycemic effect in diabetic rats. The results suggest the zwitterion-functionalized MSNs might be a good candidate for oral protein delivery.


Subject(s)
Diabetes Mellitus, Experimental , Nanoparticles , Administration, Oral , Animals , Caco-2 Cells , Diabetes Mellitus, Experimental/drug therapy , Drug Carriers/therapeutic use , Drug Delivery Systems , Gastrointestinal Tract , Humans , Porosity , Rats , Silicon Dioxide/therapeutic use
2.
Carbohydr Polym ; 229: 115508, 2020 Feb 01.
Article in English | MEDLINE | ID: mdl-31826471

ABSTRACT

Oral administration of nanoparticles is extremely limited due to the two processes of mucus permeation and epithelial absorption, which requires completely opposite surface properties of the nanocarriers. To tackle the contradiction, we developed a rational strategy to modify the surface of mesoporous carbon nanoparticles with chitosan concealed by a hydrophilic N-(2-hydroxypropyl) methacrylamide copolymer (pHPMA) layer. Probucol (PB) with the low poor permeability and solubility was loaded in optimal nanocarriers to realize the high loading efficacy and controlled release. The pHPMA polymer is a hydrophilic "mucus-inert" material, which could be dissociable from the surface of nanoparticles in the mucus, thus promoting their mucus permeation and causing exposure of chitosan in transepithelial transport. The swelling effect of chitosan under acidic conditions allowed regulation of PB release behavior. In conclusion, the mucus-permeable nanocarrier could effectively overcome multiple gastrointestinal absorption barriers and the oral bioavailability of PB-loaded HCMCN was 2.76-fold that of commercial preparation.


Subject(s)
Carbon/chemistry , Drug Carriers/chemistry , Nanoparticles/chemistry , Polymers/chemistry , Probucol/chemistry , Probucol/pharmacokinetics , Adhesiveness , Administration, Oral , Animals , Biological Availability , Drug Carriers/toxicity , Hydrophobic and Hydrophilic Interactions , Male , Materials Testing , Mice , Mucous Membrane/chemistry , Porosity , Probucol/administration & dosage
3.
Nanotechnology ; 29(34): 345101, 2018 Aug 24.
Article in English | MEDLINE | ID: mdl-29786605

ABSTRACT

In this research, a novel method was used to successfully stably coat Pluronic P123 on mesoporous silica nanoparticles (MSNs). Co-constructing a drug delivery system (DDS) with P123 and MSNs has not been previously reported. In this DDS, the coating of P123 was realized through a hydrophobic interaction with octadecyl chain-modified MSNs. The experiments found only Pluronic with an appropriate ratio of hydrophilic and lipophilic segments could keep the nanoassemblies stable. For comparison, nanoassemblies consisting of P123 and octadecyl chain-modified MSNs with or without a disulfide bond were prepared, which were denoted as PSMSNs and PMSNs, respectively. The disulfide bond was expected to endow the system with redox-responsiveness to enhance the therapeutic effect meanwhile decreasing the toxicity. A series of experiments including characterization of the nanoparticles, in vitro drug release, cell uptake and cellular drug release, in vitro cytotoxicity, cell migration and biodistribution of the nanoparticles were carried out. Compared with the PMSNs, PSMSNs displayed a redox-responsive drug release property not only in in vitro release text, but also on the cellular level. In addition, the cell migration experiments proved that the coating of P123 endowed the system with the ability of anti-metastasis. The accumulation of P123 in the tumor was enhanced after coating the MSNs by virtue of the 'EPR' effect of nanoparticles compared with the solution form.


Subject(s)
Coated Materials, Biocompatible/chemistry , Hydrophobic and Hydrophilic Interactions , Nanoparticles/chemistry , Neoplasms/drug therapy , Poloxamer/chemistry , Silicon Dioxide/chemistry , Adsorption , Animals , Cell Death/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Doxorubicin/pharmacology , Doxorubicin/therapeutic use , Drug Delivery Systems , Drug Liberation , Female , Humans , Mice, Inbred BALB C , Nanoparticles/ultrastructure , Nitrogen/chemistry , Oxidation-Reduction , Porosity , Tissue Distribution/drug effects , Wound Healing/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...